Are $CBIS / $CBIS.c management victims of circumstance, incompetent buffoons, or complicit in a fleecing of their shareholders? We don’t know, but doubt it’s the first one.
FH has done the deep dive and brought back everything you’ve ever wanted to know about $TRUL, but were afraid to ask.
Mixed results over at $APHA in Q1. Special thanks to @vanmalas, @cannabisatwork’s @AlisonLMcMahon, and my BOY @ScottW_Grizzle (can someone send him this? I’m blocked.)
The market has the hiccups, but it’s steady as she goes at $OGI. Featuring cameos by @pancakenap420 and @chernandburn Organigram Earnings give a scrambled market something to believe in
Cannabisphere all a-twitter as @chris_pelle jumps ship for $WEED. Will she still use @grizzlemedia as a source? plus: parts of that @gmpsecurities $CGC downgrade look familiar…
Breaking down the fundamentals behind the hype in the $GGB offer for $APHA.
$TLRY’s deal for Natura Naturals is putting on a clinic in risk pricing, just in time for our series on de-risking in the cannabis space.
All eyes were on $APHA Friday, as the best soap opera in the pot world arrived at the much-anticipated culmination of its latest high-drama plot arc, and payed it off in epic fashion.
$APHA is still at the top of the product mix, with $WEED close behind. Some big moves this month, including the rise of $TLRY retail and a new launch from $OGI.
This $GGB bid for $APHA scans like a stunt. But if they stick the landing, and everyone’s still watching, why stop the show?